Syschem (India) Limited manufactures Active Pharmaceuticals Ingredients (APIs) and bulk drugs.Product Profile: API/ Intermediates: a) Amoxycillin Tri Hydrate b) Ampicillin Tri Hydrate c) Cloxacillin Sodium d) Dicloxacillin Sodium e) Flucloxacillin Sodium (For export only) f) Cephalexin g) Cefixime h) Cefadroxil i) Distillation of Specialty Solvents – DMF, Acetonitrile, Ethyl Acetate...
Syschem (India) Limited has opened a special window for shareholders to re-lodge transfer requests for their physical shares. This initiative aims to streamline the process for investors holding physical certificates, ensuring their records are updated. The company has publicized this important update through newspaper advertisements in Financial Express and Rajdhani,...
Syschem (India) Limited has released its financial results for the quarter ended June 30, 2025. The company reported total income from operations of ₹126.76 Cr and a profit before tax of ₹1.67 Cr for the quarter. Earnings Per Share stood at ₹0.38. Additionally, the company has announced its 32nd Annual...
Syschem (India) Limited, a bulk drug and intermediates manufacturer, is expanding its operations. The company is constructing a new WHO-GMP compliant manufacturing unit in Kalka, Haryana, to significantly increase production capacity for key antibiotics like cloxacillin, dicloxacillin, and flucloxacillin, reinforcing its global API supplier position. Financially, the company reported a...
Syschem's Board has approved key auditor appointments. Based on the Audit Committee's input, Mr. Kanwaljit Singh was appointed Secretarial Auditor for a five-year term. M/S S T A V & Co was re-appointed as Statutory Auditor for five years. Additionally, M/S Mohit Aggarwal & Co was appointed as Cost Auditor...
Syschem (India) Limited has clarified it is not required to submit a report on fund usage deviations for the quarter ending June 30, 2025. This is because the company did not raise any funds through public, rights, preferential, or QIP issues during this period. Furthermore, there has been no deviation...
